Abstracts tagged "medication side effects and rheumatoid arthritis (RA)"

Abstract Number: 1556 • 2015 ACR/ARHP Annual Meeting
The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Delesha Carpenter¹, Lorie Geryk², Courtney Arrindell³, Beth Jonas⁴ and Susan J. Blalock⁵, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Ct, UNC-Chapel Hill, Chapel Hill, NC, ⁵School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC
Background/Purpose: We present preliminary longitudinal data about the information-seeking behaviors and medication experiences of RA patients who are prescribed a new DMARD. Methods: We recruited…
Abstract Number: 2633 • 2015 ACR/ARHP Annual Meeting
Association of Medication Beliefs, Self-Efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis
Caroline McCulley¹, Patricia P. Katz², Laura Trupin², Edward H. Yelin³ and Jennifer Barton^4,5, ¹Internal Medicine, Providence Portland Medical Center, Portland, OR, ²Rheumatology, UCSF, SF, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, OHSU, Portland, OR, ⁵Rheumatology, VA Portland Healthcare System, Portland, OR
Background/Purpose: Adherence to disease-modifying anti-rheumatic drugs (DMARDs) among rheumatoid arthritis (RA) patients ranges from 30% to 107%, leading to potential adverse outcomes. Patient beliefs about…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].